Using Beta Blockers to Treat Mitral Regurgitation
Information source: Ohio State University
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Disease; Mitral Regurgitation; Heart Valve Disease; Mitral Valve Insufficiency
Intervention: Beta-blocker therapy (TOPROL-XL® ) (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Ohio State University Official(s) and/or principal investigator(s):
Min Pu, MD, Principal Investigator, Affiliation: Ohio State University
Overall contact:
Teresa Murrell, RN, Phone: 614-688-5311, Email: Teresa.Murrell@osumc.edu
Summary
The purpose of this study tests whether a beta-blocker drug will benefit patients with
chronic mitral regurgitation.
Clinical Details
Official title: Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation
Study design: Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Assess the impact of chronic mitral regurgitation (MR) on neurohormonal activation, left ventricular remodeling, function and reserve in patients with or without surgery. Determine the effect of beta-blockade previously mentioned markers of MR.
Secondary outcome: Test new noninvasive methods to assess global and regional myocardial contractility in chronic MR, correlating the results with biochemical markers.
Detailed description:
The purpose of this study tests whether Toprol xl, a beta-blocker drug, will benefit patients
with chronic mitral regurgitation after mitral valve surgery and to investigation effects of
chronic mitral regurgitation on heart size, heart function, exercise capacity and clinical
symptoms.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- diagnosis of Mitral Regurgitation
Exclusion Criteria:
- Left ventricle ejection fraction of <55% pre and post operation
- Pregnancy or Lactation
- Secondary mitral regurgitation due to coronary artery disease, cardiomyopathy,
uncontrolled hypertension, or severe aortic stenosis.
Locations and Contacts
Teresa Murrell, RN, Phone: 614-688-5311, Email: Teresa.Murrell@osumc.edu
The Ohio State University Medical Center, Columbus, Ohio 43210, United States; Recruiting
Min PU, MD PhD, Phone: 614-293-4967, Email: Min.Pu@osumc.edu
Min PU, Md PhD, Principal Investigator
Additional Information
Starting date: October 2007
Ending date: July 2010
Last updated: January 5, 2009
|
